Page 24 - 2021_10-Haematologica-web

S.R. McCurdy and S.M. Luger
nosed cancer patients in Canada: how com- mon are they? A prospective pilot study. Drugs Aging. 2009;26(6):519-536.
11. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.
12.Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113(1):28-36.
13. Nelson ND, McMahon CM, Navarro FE, et al. Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia. Br J Haematol. 2020;191 (5):935-938.
14. McMahon CM, Nelson N, Ganetsky A, et al. Limited FISH testing for MDS-defining cytogenetic abnormalities rapidly identifies patients with newly diagnosed AML eligible for CPX-351. Blood. 2018;132(Suppl 1):4785.
15. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684- 2692.
16. Rollig C, Kramer M, Schliemann C, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020;136(7):823-830.
17. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361 (13):1249-1259.
18. Lee JH, Joo YD, Kim H, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118 (14):3832-3841.
19. Luskin MR, Lee JW, Fernandez HF, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016;127(12):1551- 1558.
20. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
21. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878- 3885.
22. Burnett AK, Russell NH, Hills RK, United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group. Higher daunorubicin exposure bene- fits FLT3 mutated acute myeloid leukemia. Blood. 2016;128(3):449-452.
23. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77(8):1666-1674.
24. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytara- bine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10(7):1103-1111.
25. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479-485.
26. WangH,XiaoX,XiaoQ,LuY,WuY.The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: a meta-analysis of randomized clinical trials. Medicine (Baltimore). 2020;99(24):e20094.
27. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood. 1981;58(6):1203-1212.
28. Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodys- plastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145(3): 318-332.
29. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027- 1036.
30. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthra- cycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131(5):561-578.
31. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879.
32. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consol- idation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586-595.
33. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302-1311.
34. Schaich M, Illmer T, Aulitzky W, et al. Intensified double induction therapy with high dose mitoxantrone, etoposide, m- amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica. 2002;87(8):808-815.
35. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75(1):27-32.
36. Norsworthy KJ, DeZern AE, Tsai HL, et al. Timed sequential therapy for acute myel- ogenous leukemia: results of a retrospective study of 301 patients and review of the liter- ature. Leuk Res. 2017;61:25-32.
37. Castaigne S, Chevret S, Archimbaud E, et al. Randomized comparison of double induc- tion and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004;104(8):2467-2474.
38. Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induc- tion prolongs survival of patients with acute myeloid leukemia: a multicenter, random- ized phase III study. J Clin Oncol. 2012;30(20):2441-2448.
39.Pluta A, Robak T, Wrzesien-Kus A, et al. Addition of cladribine to the standard induc- tion treatment improves outcomes in a sub- set of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Am J Hematol. 2017;92(4):359-366.
40. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the
41.
addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta- analysis of individual patient data from ran- domised controlled trials. Lancet Oncol. 2014;15(9):986-996.
42.Schlenk RF, Paschka P, Krzykalla J, et al. Gemtuzumab ozogamicin in NPM1-mutat- ed acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study. J Clin Oncol. 2020;38(6):623-632.
43. Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374 (5):422-433.
44. Mosna F, Papayannidis C, Martinelli G, et al. Complex karyotype, older age, and reduced first-line dose intensity determine poor sur- vival in core binding factor acute myeloid leukemia patients with long-term follow-up. Am J Hematol. 2015;90(6):515-523.
45. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464.
46. Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840-851.
47. Pratz KW, Cherry M, Altman JK, et al. Updated results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML). Blood. 2018;132(Suppl 1):564.
48. Juliusson G, Hagberg O, Lazarevic VL, et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134(18):1558-1561.
49. Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk. 2011;11(Suppl 1):S54-59.
50. Bories P, Bertoli S, Berard E, et al. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional health- care network. Am J Hematol. 2014;89(12): E244-252.
51. Orvain C, Tanguy-Schmidt A, Thepot S, et al. Validation of the revised AML-composite model for the prediction of prognosis in older patients receiving intensive induction therapy. Blood. 2019;134(Suppl 1):1310.
52.Elsayed S, Storer BE, Medeiros BC, et al. Augmentation of the acute myeloid leukemia-composite model (AML-CM) with performance status and secondary leukemia. Blood. 2018;132(Supplement 1):3992.
53.
Sorror ML, Storer BE, Fathi AT, et al. Multi- site 11-year experience of less-intensive ver- sus intensive therapies in acute myeloid leukemia. Blood. 2021;138(5):387-400.
54.Heiblig M, Le Jeune C, Elhamri M, et al. Treatment patterns and comparative effec- tiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon- university hospital experience. Leuk Lymphoma. 2017;58(1):110-117.
55. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable
2552
haematologica | 2021; 106(10)